Whereas back in the nineties they were skeptical, now they seem convinced," said Mark Schoenebaum, an analyst with International Strategy & Investment.
Pharma's niche focus spurs US aid for antibiotics →
ISI analyst Mark Schoenebaum said the FDA's negative review was consistent with analyst expectations.
FDA questions Amgen drug for prostate cancer →
Be the first to know